ImpediMed logo

ImpediMed(OTC) IPDQF

Market Cap$16.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2008)-99%
5 Year-95%
1 Year-88%
1 Month-16%
$0.00
-18.18%
-0.00Today
ImpediMed last closing stock price
MetricPriceDate
Last closeUSD 0.002026-10-02
ImpediMed stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-18.18%USD 0.012026-09-24
1 month-15.89%USD 0.012026-09-02
3 month-9.46%USD 0.002026-06-29
Year to date-79.55%USD 0.022025-12-23
1 year-88%USD 0.042025-10-02
3 year-95.77%USD 0.112023-10-02
5 year-94.98%USD 0.092021-09-29
Since inception-98.95%USD 0.432008-11-13

ImpediMed Financials at a Glance

Market Cap

$16.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

A$27.32M

Net Income (TTM)

-A$48.12M

EPS (TTM)

-$0.01

P/E Ratio

-0.57

Dividend

$0.00

Beta (Volatility)

0.32 (Low)

Price

$0.00

Volume

470,000

Open

$0.00

Previous Close

$0.00

Daily Range

$0.00 - $0.01

52-Week Range

$0.00 - $0.03

Estimated Earnings Date

Feb 25, 2027

IPDQF News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About ImpediMed

ImpediMed Limited is a medical technology firm specializing in software solutions and bioimpedance spectroscopy (BIS) equipment. The company focuses on the creation, production, and global distribution of advanced medical devices, primarily serving healthcare institutions in Australia, North America, and beyond.

Products and Services
  • SOZO: A non-intrusive BIS device for evaluating lymphedema and tracking fluid levels
  • SFB7: A single-channel BIS instrument for assessing body composition in healthy individuals
  • ImpediVET: A BIS device tailored for veterinary applications to measure fluid status in animals
Growth Outlook
  • Expansion into North American markets is underway, increasing potential customer base
  • Continued investment in R&D aims to enhance product offerings and technology
  • Strategic partnerships with healthcare institutions may drive future revenue growth
Financial Highlights
  • Recent quarterly revenue of 7.09 million AUD, showing potential for growth
  • Cash and cash equivalents of 15.26 million AUD, providing operational stability
  • Current ratio of 3.81 indicates strong liquidity position
ImpediMed Limited is positioned in the medical devices industry, focusing on innovative solutions that address critical healthcare needs. The company's flagship products, such as SOZO and ImpediVET, cater to both human and veterinary markets, showcasing versatility in application. The growth outlook is promising, with strategic initiatives aimed at expanding market reach and enhancing product capabilities. Financially, the company has demonstrated resilience with a significant cash reserve, which supports ongoing operations and potential growth initiatives. The current ratio indicates a robust liquidity position, allowing for flexibility in navigating market challenges. Recent revenue figures suggest a positive trajectory, reflecting the company's ability to capitalize on emerging opportunities in the healthcare sector. Overall, ImpediMed Limited presents an intriguing option for investors interested in the medical technology landscape.
AI Generated • Oct 8, 2026

Industry

Healthcare Equipment and Supplies

Sector

Health Care

Employees

66

CEO

Erik S. Anderson, CFA

Website

www.impedimed.com

Headquarters

Carlsbad, CA 92008, US

IPDQF Financials

Key Financial Metrics (TTM)

Gross Margin

-81.36%

Operating Margin

-117.21%

Net Income Margin

-170.44%

Return on Equity

-259.31%

Return on Capital

-206.67%

Return on Assets

-71.86%

Earnings Yield

-1.75%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$16.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

3.66B

Volume

470.00K

Avg. Volume

26.26K

Financials (TTM)

Gross Profit

-A$903.91K

Operating Income

-A$41.34M

EBITDA

-A$32.56M

Operating Cash Flow

-A$34.66M

Capital Expenditure

A$19.95M

Free Cash Flow

-A$14.71M

Cash & ST Invst.

A$15.26M

Total Debt

A$508.29K

ImpediMed Performance Analysis

ImpediMed annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20232023-06-30AUD 7,631,160-0.4%
20242024-06-30AUD 6,762,815-11.4%
20252025-06-30AUD 8,240,45721.8%
20262026-06-30AUD 9,902,10420.2%
ImpediMed sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-318.5%
Q42025-06-3011.8%
Q22025-12-3111.9%
Q42026-06-30-5.7%
ImpediMed annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20232023-06-30AUD -0.01-10.5%
20242024-06-30AUD -0.01-16.9%
20252025-06-30AUD -0.0117.2%
20262026-06-30AUD -0.015.3%
ImpediMed sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22024-12-3130.6%
Q42025-06-30-76.5%
Q22025-12-31N/A
Q42026-06-306.7%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q4 2026YOY CHG

Revenue

A$7.09M

+28.0%

Gross Profit

-A$5.37M

-210.6%

Gross Margin

-75.71%

N/A

Market Cap

$16.48MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$249.72K

N/A

Employees

66

N/A

Net Income

-A$12.61M

-25.2%

EBITDA

-A$7.50M

+25.0%

Quarterly Fundamentals

Name
Q4 2026YOY CHG

Total Cash

A$15.26M

-38.0%

Total Debt

A$508.29K

-55.5%

Accounts Receivable

A$4.67M

+112.9%

Inventory

A$2.21M

+190.9%

Long Term Debt

A$212.70K

-73.7%

Short Term Debt

A$295.58K

-11.2%

Return on Assets

-71.86%

N/A

Return on Invested Capital

-60.13%

N/A

Free Cash Flow

A$0.00

+100.0%

Operating Cash Flow

-A$10.51M

+4.5%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
PYNKFPerimeter Medical Imaging AI, Inc.
$0.16+2.50%
CLYYFCelyad Oncology S.A.
$0.28+0.00%
CNTMFFluent Corp.
$0.02+0.63%
ELXMFNova Eye Medical Limited
$0.01+0.00%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$107.08-5.34%
NVDANvidia
$230.48-2.94%
SOXSDirexion Shares ETF Trust - Direxion Daily Semiconductor Bear 3x ETF
$33.79+10.24%
BITOProShares Trust - ProShares Bitcoin ETF
$10.93-1.88%

Questions About IPDQF

What is the current price of ImpediMed?

ImpediMed is trading at $0.00 per share.

What is the 52-week range for ImpediMed?

Over the past 52 weeks, ImpediMed has traded between $0.00 and $0.03.

How much debt does ImpediMed have?

As of the most recent reporting period, ImpediMed reported total debt of A$11.50M.

How much cash does ImpediMed have on hand?

ImpediMed reported A$10.59M in cash and cash equivalents in its most recent financial results.

What is ImpediMed’s dividend yield?

ImpediMed does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services